Setting future standards for KRAS testing in colorectal cancer. - Wikidata - wikimedia - TriplyDB

Setting future standards for KRAS testing in colorectal cancer.

Setting future standards for KRAS testing in colorectal cancer.

http://www.wikidata.org/entity/Q54778813

about

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme.Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.

P2860

Q28082816-8BD39684-6960-4CF6-B3A0-A8F3A47968CE Q33723645-0D995257-F575-46EF-9D23-BA3CEA429693 Q35125613-4BD25A42-5802-4446-8098-9FA307416067 Q35584550-1C995CDE-1087-4EB7-9CCD-9275370210E3 Q36089983-35AA1D91-268B-498F-B4EE-34EE32808C2D Q36334805-66B1B395-FE44-4B47-9BA5-11108F439C30 Q37231968-17AB71FC-B2DD-4FD6-B3B4-38DB4DCA955C Q39736095-683FFB23-1F95-4ED0-A35A-72C293DCEC06 Q42583248-79437F99-EC64-4D25-8D9E-26E51E070659 Q44193651-9085C83B-5378-46AA-B36D-D81FE451DF30

P2860

Setting future standards for KRAS testing in colorectal cancer.

http://www.wikidata.org/entity/Q54778813

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Setting future standards for KRAS testing in colorectal cancer.

@en

Setting future standards for KRAS testing in colorectal cancer.

@nl

type

label

Setting future standards for KRAS testing in colorectal cancer.

@en

Setting future standards for KRAS testing in colorectal cancer.

@nl

prefLabel

Setting future standards for KRAS testing in colorectal cancer.

@en

Setting future standards for KRAS testing in colorectal cancer.

@nl

P1433

Q54778813-98568F58-3AA0-4904-9093-A61DC071C975

P1476

Q54778813-F0E8FA82-0369-4CA5-AD05-796790DAB843

P2093

Q54778813-5436EB8B-2398-4225-85F6-F74036CAFFB1

Q54778813-5C3BDBE1-2150-46BF-A056-3816A9141DC2

P2860

Q54778813-69536EB1-10CA-4CD5-A859-CC6A7BC19FE1

Q54778813-6DF3F2EF-C107-44CE-B145-9614455C491B

Q54778813-7002D98A-D649-47B8-8C0A-F9DFE3D9D156

Q54778813-7529BFBB-B0DF-4B94-BD22-8D9310C82BEB

Q54778813-8DD29B4E-4846-4BEE-B67B-AD197A382559

Q54778813-9B4B9535-41B7-4B1D-952C-304107CB0E5D

Q54778813-AD14BB4E-FAA9-498E-A45F-3E384146095A

Q54778813-B35F4F47-3F6A-4C75-87F4-210162384A07

Q54778813-B719E2B5-091F-4E7F-A1B0-F3049AFBCE53

Q54778813-BE37F6E6-0A72-45CE-84AC-3346272D7462

P304

Q54778813-3BE2F6D6-485C-4F49-BFA4-4E36E60849C8

P31

Q54778813-181F11F7-8A30-4351-B1F0-FBC7B19EA360

Q54778813-ed0cc2ff-7bce-4fd7-9a58-749c9f131d67

P356

Q54778813-E5966A81-8C67-433C-A7EE-6B36D3CDEE0C

P433

Q54778813-C4C46F51-FBEB-438C-8ADC-C4757D2266C1

P478

Q54778813-FDBBA253-2DA0-4A37-B8E1-77615B0F0798

P577

Q54778813-36D9815E-195D-428D-A979-0DECBAFFDD7C

P698

Q54778813-6744928F-71B0-4B0B-89C1-9776BB112678

P921

Q54778813-D131FF99-5C20-4FAA-B31E-EA1BA2AD4C43

P356

14622416.10.1.1

P1433

Pharmacogenomics

P1476

Setting future standards for KRAS testing in colorectal cancer.

@en

P2093

Han van Krieken

http://www.w3.org/2001/XMLSchema#string

Jolien Tol

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.

P304

1-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.10.1.1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19102707

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer